新冠疫苗产生数万亿美元收益,远超其成本
COVID-19 vaccines generated trillions in benefits, far exceeding their estimated costs
研究显示,每投入一美元用于新冠疫苗的研发和分发,可获得81至810美元的经济回报。高收入国家因早期接种和高接种率获益最大,而低收入国家尽管较晚接种,仍避免了大量医疗和生产力损失。研究强调疫苗公平分配的重要性。
研究量化了新冠疫苗的经济收益,显示其投资回报远超成本,强调了疫苗公平分配的重要性。
Every dollar spent on COVID-19 vaccine development and distribution generated an estimated $81 to $810 in economic value during the first year that vaccines were given, according to new research published in the journal PLOS Medicine.
The study—the first global analysis of the return on investment for COVID-19 vaccines—shows that vaccines not only averted severe illness and saved lives but were also a sound investment.
"Our study provides evidence that the unprecedented, rapid investments made into COVID-19 vaccines early in the pandemic paid off massively both in health and economic benefits," said study author Mark Jit, professor of global health at NYU School of Global Public Health. "Vaccine development, as well as equitable vaccine distribution globally, should be prioritized before and during global health crises."
Counting costs beyond vaccine purchases
Vaccines played a critical role during the COVID-19 pandemic, but their development required extraordinary effort—and spending—among governments, pharmaceutical companies and nonprofit organizations. The resulting vaccines were highly effective at preventing severe illness and death, with one study estimating that between 14 million and 20 million deaths were averted in the first year that vaccines were available.
Despite their health impact, the economic value of these vaccines has not been examined on a global scale. Moreover, most analyses of the cost-effectiveness of immunization look at the cost of purchasing the vaccine itself from its manufacturer, not the cost of developing it.
"With other vaccines, a company takes on the risk by investing its own money to develop a vaccine. But the COVID vaccine was not purely a private sector decision—the U.S., the European Union and other countries like China poured substantial funding into this to reduce the risk for vaccine companies," said Jit. "We wanted to understand how these costs compared to health and economic outcomes."
Measuring the first year's returns
To measure the impact of this investment, the researchers evaluated the economic value of COVID-19 vaccines during the first year that vaccines became available (Dec. 8, 2020–Dec. 8, 2021), when they had the greatest impact because people had limited immunity to the virus.
Using data from 173 countries, the researchers compared the costs of vaccine development, manufacturing and delivery with health and economic measures related to the vaccine. These included years of life gained, quality-of-life measures from avoiding hospitalizations and deaths, work productivity and averted health care costs.
The researchers then used two different methods to quantify the value of saving lives and improving health: a cost-benefit analysis commonly used in the public sector, as well as a cost-effectiveness analysis used in the health sector to quantify savings based on what would be spent in health care to save someone's life.
Overall, COVID-19 vaccine development and delivery worldwide cost $79.4 billion, but the health and economic benefits of vaccination were valued between $6.43 trillion and $64.3 trillion, translating to a return on investment of $81 to $810 per dollar spent.
"While developing and rolling out these vaccines at unprecedented speed required substantial upfront investment, the health and economic benefits far outweighed the costs within just one year," said Hallie Benjamin, lead author of the paper who worked on the research as an MSc student in public health at the London School of Hygiene & Tropical Medicine (LSHTM).
Unequal access shaped national benefits
The researchers found significant disparities in the vaccine's return on investment across countries, with high-income countries benefiting more than low- and middle-income countries. High-income countries gained the greatest economic benefits due to early access, higher uptake of vaccines, faster rollouts and older populations who were at risk for severe outcomes.
In contrast, many low- and middle-income countries didn't have widespread access to the vaccine until late 2021, after many people had already contracted COVID-19 and developed some immunity. Despite this, low-income countries still had the highest averted health care and productivity costs relative to their own economies and populations.
"The lesson is there should be a way to get this vaccine to countries that need it faster. Because of the delays, it wasn't as useful to many of those countries as it could have been," said Jit.
Preparing for the next viral threat
The authors note that the study does not examine the economic benefit of COVID-19 vaccines beyond their first year, when rates of infection were lower and most people had developed some immunity. But in the face of a new viral threat, the findings show that rapidly investing in vaccine development can safeguard public health and preserve economic stability.
"By preventing billions of infections and millions of hospitalizations and deaths, the vaccines generated enormous value for societies and economies worldwide. However, our research also shows that these benefits were not shared equally between higher- and lower-income countries, highlighting the importance of equitable and timely vaccine distribution. Through studying these inequalities, we hope our findings can help guide future research into how vaccination programs can improve health and economic outcomes worldwide," said Benjamin.
Additional study authors include Gregory Barnsley of LSHTM and Oliver Watson of Imperial College London.
Publication details
A global return-on-investment of COVID-19 vaccines in the first year of the vaccination programme: A model-based economic evaluation, PLOS Medicine (2026). journals.plos.org/plosmedicine … journal.pmed.1004772
Journal information: PLoS Medicine
Who's behind this story?
Swati Mestri
Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: COVID-19 vaccines generated trillions in benefits, far exceeding their estimated costs (2026, November 5) retrieved 5 November 2026 from https://medicalxpress.com/news/2026-11-covid-vaccines-generated-trillions-benefits.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com